<

EDISON INVESTMENT RESEARCH LIMITED (LON:KEFI) Edison Investment Research Limited: Edison issues update on Silence Therapeutics (SLN)

Transparency directive : regulatory news

25/03/2020 15:55

Edison Investment Research Limited
Edison Investment Research Limited: Edison issues update on Silence Therapeutics (SLN)

25-March-2020 / 14:55 GMT/BST


 

London, UK, 25 March 2020

Edison issues update on Silence Therapeutics (SLN)

Silence Therapeutics announced on 25 March 2020 that it has signed a collaboration agreement with AstraZeneca to develop novel drugs for cardiovascular, renal, metabolic and respiratory diseases. The deal includes an upfront of $60m, $20m in equity investment, and for each of the planned targets $400m in milestones, and high single- to low double-digit royalties. Additionally, the company announced that it would elevate SLN360 to the status of lead asset and expects to file an IND later in 2020 and to have interim results in mid-2021.

 

We have increased our valuation to £462m or 559p per basic share, from £345m or 440p per basic share. This is driven by the addition of the AstraZeneca deal metrics and its associated cash injections to our models (total £74m value uplift), an increase in the valuation of SLN360 to £167m from £112m and offset by the delay to SLN124 (£129m from £141m).


Click here to view the full report.

 

Subscribe to Edison's content to receive reports by email.

All reports published by Edison are free-to-access and available on the website.

 

About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information please contact Edison:

Nathaniel Calloway, +1 646 653 7036

healthcare@edisongroup.com

 

Learn more at www.edisongroup.com and connect with Edison on: 

LinkedIn        https://www.linkedin.com/company/edison-group-

Twitter           www.twitter.com/Edison_Inv_Res

YouTube       www.youtube.com/edisonitv



Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

1007125  25-March-2020 

fncls.ssp?fn=show_t_gif&application_id=1007125&application_name=news&site_id=symex


Other stories

28/03/2024 20:19
28/03/2024 21:18
28/03/2024 13:03
28/03/2024 18:06
29/03/2024 00:02
28/03/2024 23:45
29/03/2024 00:59
28/03/2024 12:26
28/03/2024 22:17
28/03/2024 21:42
28/03/2024 19:33
28/03/2024 19:16
28/03/2024 22:03
28/03/2024 22:21
29/03/2024 00:59
28/03/2024 19:01
28/03/2024 23:13
28/03/2024 17:05
27/03/2024 15:52
27/03/2024 19:23
28/03/2024 21:30
28/03/2024 09:00
28/03/2024 23:39
28/03/2024 08:35
28/03/2024 23:00
28/03/2024 19:13
29/03/2024 00:17
29/03/2024 00:37
28/03/2024 10:25
28/03/2024 17:34
27/03/2024 21:46
28/03/2024 17:55
29/03/2024 01:26
27/03/2024 13:40
29/03/2024 00:01
28/03/2024 13:25
28/03/2024 12:57
28/03/2024 16:44